Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 288

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 288
---
 Company is unable to complete the initial Business Combination within the required time period and the Company will redeem the public shares for the funds held in the Trust Account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless. NOTE 8 — SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet and through the date that the financial statements were issued. Based upon this review, other than as noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. On October23, 2024, the Company and EF Hutton LLC mutually agreed to terminate their agreement. As part of the termination agreement, if the Company, for a period of twelve months after this termination agreement, consummates an initial public offering of its securities, the Company shall pay to EF Hutton LLC a fee in cash in the amount of $100,000, upon the consummation of such offering. In connection with the decrease in the Proposed Public Offering, on November6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor holds 9,857,143 Founder Shares. All share and per share data has been retrospectively presented. On November21, 2024, the Sponsor amended the Promissory Note to increase the amount the Company may borrow up to $750,000. All other terms of the note remained the same. On December5, 2024, the Sponsor further amended the Promissory Note to increase the amount the Company may borrow to $1,850,000. The Promissory Note shall be due and payable upon the closing of the Company’s initial business combination or upon the Company’s dissolution, whichever occurs first. F-15 20,000,000 Units Drugs Made In America Acquisition Corp. _________________________________________________ PRELIMINARY PROSPECTUS , 2025 _________________________________________________ Sole Book -Running Manager Clear Street Until, 2025 (25 days after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions.

PART II Information not required in prospectus ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. The estimated expenses